People searching “TB-500 side effects” usually want a straight answer: what can this peptide do to me, how likely is it, and how bad can it get? Here is the honest headline: there are essentially no published human safety studies of TB-500 itself. The reassuring “well tolerated” claims that circulate online come from clinical trials of a different, longer molecule — full-length thymosin β4 — given short-term under medical supervision, not from the TB-500 sold as a research chemical. On top of that, laboratory research flags a real theoretical cancer-promotion concern, and the long-term effects of self-injecting TB-500 are simply unknown. This page is a research-use-only (RUO) reference and is not medical advice.
Chemistry first, because it drives everything else. Independent analyses of commercial “TB-500” products show the active ingredient is not whole thymosin β4 but a synthetic, N-terminally acetylated fragment of it — the 17–23 actin-binding region, Ac-LKKTETQ (Esposito et al., 2012; Ho et al., 2012). So when a seller cites “thymosin β4 clinical trials” as proof TB-500 is safe, that is a substitution the evidence does not support.
Documented side effects
The table below separates clinical (human-trial) findings from preclinical (lab/animal) and analytical evidence. Every human tolerability figure comes from trials of full-length thymosin β4, not the TB-500 fragment.
General / infusion-related adverse events
Infrequent, mild-to-moderate; no serious adverse events or dose-limiting toxicity in short-term dosing
Clinical — Ruff 2010; Wang 2021 (full-length Tβ4, IV, ≤14 days)
Anti-drug antibodies (immunogenicity)
Built into trial protocols as a monitored risk; peptides can provoke immune responses
Clinical — Wang 2021; trial NCT04555850
Tumour-promoting activity (angiogenesis, anti-apoptosis, cell migration/EMT)
Serious but theoretical; observed in cell/tumour models, not reported as a human-trial side effect
Preclinical — Smart 2007; Xing 2021; Jin 2025
Long-term / chronic self-injection effects
Unknown — no human data exist
Evidence gap (none identified)
In plain terms: in short Phase 1 dosing of full-length thymosin β4, adverse events were “infrequent, and mild or moderate,” with no serious adverse events and no dose-limiting toxicity (Ruff et al., 2010, DOI; Wang et al., 2021, DOI; indexed in PubMed). That is genuinely reassuring for that molecule, that route, and that timeframe — and it tells us very little about weeks-to-months of unregulated TB-500 self-injection.
The serious signal is preclinical. The same properties that make thymosin β4 attractive for tissue repair — promoting angiogenesis, cell migration and survival while suppressing programmed cell death — are also mechanisms that can favour tumour growth. Reviews and mechanistic work describe Tβ4 driving angiogenesis and tumour progression (Smart et al., 2007; Xing et al., 2021), and a 2025 study reported that Tβ4 promotes breast-cancer proliferation, migration, EMT and angiogenesis, with high expression linked to worse clinical outcomes (Jin et al., 2025). This is a laboratory concern, not a confirmed human side effect — but it is exactly the kind of risk that “no long-term human data” leaves completely unmonitored.
Who is at higher risk / contraindications
Anyone with active or prior cancer, or a strong family history: the documented pro-angiogenic and anti-apoptotic mechanisms are a theoretical concern with no human safety data to offset it (Smart 2007; Xing 2021; Jin 2025).
Pregnant or breastfeeding individuals: uniformly excluded from thymosin β4 trials; no safety data.
People with peptide/protein hypersensitivity: immunogenicity (anti-drug antibodies) is a recognised, protocol-monitored risk (Wang 2021).
Tested / competitive athletes: TB-500 and thymosin β4 are prohibited in sport by WADA and the equine authorities FEI and IFHA (Delcourt et al., 2024). Use risks sanctions independent of any health effect.
Anyone who cannot verify product identity and purity: TB-500 circulates as non-authorised products sold online (Delcourt 2024), so contamination and mislabelling are unquantified additional risks.
What we do NOT know
For a “research peptide” like TB-500, the gaps are not a footnote — they are the main risk. Absence of evidence here means absence of safety monitoring, not evidence of safety.
There is no completed human safety trial of the TB-500 fragment (Ac-LKKTETQ) itself.
No data exist on the subcutaneous gray-market dosing and schedules people actually use.
No long-term or chronic-use human data exist — the reassuring trials lasted days to a few weeks.
No thymosin β4 product has been approved by the FDA or EMA for any use, despite years of trials (several of which were terminated or withdrawn).
The cancer question is unanswered in humans: a plausible mechanistic risk with no clinical outcome data either way.
Drug interactions, effects on people with chronic disease, and product-to-product variability are all uncharacterised.
Dosage & handling reference
Because TB-500 is not an approved medicine, there is no validated human dose — any figures you see are laboratory conventions, not clinical guidance. For reconstitution and unit-conversion documentation used in a research setting only, see our TB-500 dosage reference and the general peptide dosage calculator. These tools exist to document handling accurately; they are not human-use instructions and do not imply the compound is safe or effective.
FAQ
Is TB-500 proven safe in humans?
No. There are no completed human safety trials of the TB-500 fragment. The only human tolerability data are for full-length thymosin β4 — a different molecule — tested short-term under supervision (Ruff 2010; Wang 2021).
Do the thymosin β4 clinical trials apply to TB-500?
Not directly. Commercial TB-500 is a synthetic 17–23 fragment (Ac-LKKTETQ), not whole thymosin β4 (Esposito 2012; Ho 2012), so trial results for the full peptide cannot be assumed to transfer.
Can TB-500 cause cancer?
There is no human evidence either way. However, preclinical studies show thymosin β4 can promote angiogenesis, cell migration and tumour progression (Smart 2007; Xing 2021; Jin 2025), so the concern is real and simply unresolved. This is one reason the unknown long-term safety matters.
This article is for research documentation and general information only. It is not medical advice, and TB-500 is not an approved treatment. Consult a qualified healthcare professional before making any health decision.